Introduction
Approximately 10% to 30% of the worldwide population suffers from allergic diseases. In these currently available drugs, ebastine (EBT), as a potent second-generation H1 histamine receptor antagonist, is commonly recommended for treatment of a wide range of allergies, such as rhinitis, urticaria and allergic contact dermatitis.1,2 Although oral delivery of ebastine is preferred, its therapeutic effect is compromised due to its poor water solubility, which limits absorption in physiological fluids and results in inadequate therapeutic function. As far as a BCS-II drug is concerned, it is reported that there is only about 40% bioavailability of ebastine is achieved after oral administration.3 Furthermore, the traditional oral administration method fails to…